The researchers concluded that rituximab should be considered as a preferred biologic treatment for rheumatoid arthritis (RA) therapy, though treatment of RA with any biologic medication improved quality of life significantly.
A recent study, based on real-world experience in Bulgaria, looked to compare the quality of life (QOL) benefits and the cost of biologic therapeutic options for the treatment of rheumatoid arthritis (RA).
In the observational study, researchers enrolled 124 patients treated with biological medicines after receiving prior treatment with conventional drugs from 2012 to 2016 at a university hospital in Bulgaria. QOL was assessed through the European Quality 5-Dimensions (EQ5D) questionnaire at the beginning of therapy, after 6 months, and 1 year.
Physicians were able to choose the biologic medicine prescribed to their patient based on clinical status of the patients and the available medicines on the hospital’s reimbursement list. Patients in the study took the following therapies: tocilizumab (n = 30), certolizumab pegol (n = 16), golimumab (n = 22), etanercept (n = 20), adalimumab (n = 20), and rituximab (n = 16).
Click here to read more about biologic therapies in RA.
To evaluate the cost effectiveness of each respective product, researchers built a decision-tree model using software to compare the yearly pharmacotherapy cost with the changes in EQ5D scores after 1 year of biologic therapy.
Through the evaluation, researchers confirmed that the QOL improvement produced by biologic therapy is statistically significant. Specifically, as measured by EQ5D, QOL improves quickly at the beginning of therapy and subsequently slows down toward the end of 1 year of therapy.
However, though each drug was found to improve the QOL of RA patients, only rituximab was identified to be cost-effective.
“Biological medicines appear not to be cost-effective due to their high incremental cost-effectiveness ratio,” the authors noted. Rituximab’s incremental cost-effectiveness ratio falls close to being 3 time the gross domestic product per capita threshold.
The researchers concluded that rituximab should be considered as a preferred biologic treatment for RA therapy, though treatment of RA with any biologic medication improves quality of life significantly.
Reference
Boyadzieva V, Stoilov N, Stoilov R, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794. doi: 10.3389/fphar.2018.00794.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.